中华眼科杂志
中華眼科雜誌
중화안과잡지
Chinese Journal of Ophthalmology
2012年
12期
1083-1087
,共5页
幼牛血清%成纤维细胞生长因子2%角膜疾病%治疗结果
幼牛血清%成纖維細胞生長因子2%角膜疾病%治療結果
유우혈청%성섬유세포생장인자2%각막질병%치료결과
Actihaemyl%Fibroblast growth factor 2%Corneal diseases%Treatment outcome
目的 探讨小牛血去蛋白提取物眼用凝胶治疗弥漫性角膜上皮点状脱落的临床疗效.方法 收集36例(36只眼)弥漫性角膜上皮点状脱落患者,随机分为2组,其中小牛血去蛋白提取物组(试验组)19例,重组牛碱性成纤维细胞生长因子眼用凝胶组(对照组)17例.两组均每天4次,每次1滴,疗程14 d.用药前和用药后14 d分别进行角膜染色评分、泪膜破裂时间(BUT)、Schirmer泪液分泌试验(SⅠt)和视力的评估.根据数据的正态分布和方差齐性选择合适的统计方法.计量资料采用t检验,不符合正态性及方差不齐时,采用Wilcoxon非参数法,同组前后比较采用配对t检验.计数资料采用卡方、校正卡方、Fisher精确检验等.结果 用药后14d,试验组与对照组角膜染色评分较基线期分别下降(3.895±2.307)和(2.235±2.047),差异有统计学意义(t=5.7083,4.5019；P＜0.01).且两组间下降幅度差异有统计学意义(t=2.2712,P =0.0296).两组治疗14 d后的BUT均较基线期明显增加(Z =2.226,2.527；P＜0.05),但组间差异无统计学意义(Z=1.336,P=0.1815).治疗14 d后,试验组与对照组的SⅠt结果较基线期变化无统计学意义(t=0.4207,1.1255；P＞0.05),组间差异无统计学意义(t=0.9830,P=0.3325).两组视力变化较基线期无统计学意义(Z=1.897,1.786;P＞0.05).结论 小牛血去蛋白提取物眼用凝胶治疗弥漫性角膜上皮脱落疗效确切,且优于重组牛碱性成纤维细胞生长因子眼用凝胶.
目的 探討小牛血去蛋白提取物眼用凝膠治療瀰漫性角膜上皮點狀脫落的臨床療效.方法 收集36例(36隻眼)瀰漫性角膜上皮點狀脫落患者,隨機分為2組,其中小牛血去蛋白提取物組(試驗組)19例,重組牛堿性成纖維細胞生長因子眼用凝膠組(對照組)17例.兩組均每天4次,每次1滴,療程14 d.用藥前和用藥後14 d分彆進行角膜染色評分、淚膜破裂時間(BUT)、Schirmer淚液分泌試驗(SⅠt)和視力的評估.根據數據的正態分佈和方差齊性選擇閤適的統計方法.計量資料採用t檢驗,不符閤正態性及方差不齊時,採用Wilcoxon非參數法,同組前後比較採用配對t檢驗.計數資料採用卡方、校正卡方、Fisher精確檢驗等.結果 用藥後14d,試驗組與對照組角膜染色評分較基線期分彆下降(3.895±2.307)和(2.235±2.047),差異有統計學意義(t=5.7083,4.5019；P＜0.01).且兩組間下降幅度差異有統計學意義(t=2.2712,P =0.0296).兩組治療14 d後的BUT均較基線期明顯增加(Z =2.226,2.527；P＜0.05),但組間差異無統計學意義(Z=1.336,P=0.1815).治療14 d後,試驗組與對照組的SⅠt結果較基線期變化無統計學意義(t=0.4207,1.1255；P＞0.05),組間差異無統計學意義(t=0.9830,P=0.3325).兩組視力變化較基線期無統計學意義(Z=1.897,1.786;P＞0.05).結論 小牛血去蛋白提取物眼用凝膠治療瀰漫性角膜上皮脫落療效確切,且優于重組牛堿性成纖維細胞生長因子眼用凝膠.
목적 탐토소우혈거단백제취물안용응효치료미만성각막상피점상탈락적림상료효.방법 수집36례(36지안)미만성각막상피점상탈락환자,수궤분위2조,기중소우혈거단백제취물조(시험조)19례,중조우감성성섬유세포생장인자안용응효조(대조조)17례.량조균매천4차,매차1적,료정14 d.용약전화용약후14 d분별진행각막염색평분、루막파렬시간(BUT)、Schirmer루액분비시험(SⅠt)화시력적평고.근거수거적정태분포화방차제성선택합괄적통계방법.계량자료채용t검험,불부합정태성급방차불제시,채용Wilcoxon비삼수법,동조전후비교채용배대t검험.계수자료채용잡방、교정잡방、Fisher정학검험등.결과 용약후14d,시험조여대조조각막염색평분교기선기분별하강(3.895±2.307)화(2.235±2.047),차이유통계학의의(t=5.7083,4.5019；P＜0.01).차량조간하강폭도차이유통계학의의(t=2.2712,P =0.0296).량조치료14 d후적BUT균교기선기명현증가(Z =2.226,2.527；P＜0.05),단조간차이무통계학의의(Z=1.336,P=0.1815).치료14 d후,시험조여대조조적SⅠt결과교기선기변화무통계학의의(t=0.4207,1.1255；P＞0.05),조간차이무통계학의의(t=0.9830,P=0.3325).량조시력변화교기선기무통계학의의(Z=1.897,1.786;P＞0.05).결론 소우혈거단백제취물안용응효치료미만성각막상피탈락료효학절,차우우중조우감성성섬유세포생장인자안용응효.
Objective To evaluate the clinical efficacy of protein-free calf blood extract ophthalmic gel for diffuse punctate corneal epithelial defects.Methods 36 patients (36 eyes) with diffuse punctate corneal epithelial defects were enrolled between Oct.2008 and Apr.2009 in outpatient clinic from Eye Ear Nose and Throat Hospital of Fudan University.Patients were randomized divided into protein-free calf blood extract ophthalmic gel group (the test group,19 eyes)and recombinant bovine basic fibroblast growth factor ophthalmic gel group (the control group,17 eyes).The drugs were delivered in both groups 4 times per day,one drop each time in the 14 days duration.Corneal staining,the tear break-up time,the Schirmer value and visual acuity were evaluated on the pre-delivery day and the post-delivery day 14.Results On day 14,both the test group and control group had a significant decrease from baseline in corneal staining (the test group t =5.7083,P =0.0000 and the control group t=4.5019,P=0.0004,respectively).And improvements of corneal staining in the test group was more significant than that in the control group (t=2.2712,P =0.0296).Improvements were seen in BUT values in both group on day 14,as compared to baseline (the test group Z =2.226,P =0.0260 and the control group Z =2.527,P =0.0115,respectively).However,there was no significant difference between groups (Z =1.336,P =0.1815).As to the Schirmer value,there were neither difference within groups from baseline (the test group t =0.4207,P =0.6790 and the control group t =1.1255,P =0.2770,respectively).Nor between groups (t=0.9830,P=0.3325).And no obvious changes from baseline in visual acuity were observed in both groups (the test group Z =1.897,P=0.0578 and the control group Z =1.786,P =0.0741,respectively).Conclusion The efficacy of protein-free calf blood extract ophthalmic gel is prior to recombinant bovine basic fibroblast growth factor ophthalmic gel in patients with diffuse punctate corneal epithelial defects.
